This image illustrates MRI with geometric distortion correction for SRS treatment planning.
This correction supports tumor-target alignment and treatment margin management.
Tumor-Target Alignment
Supports tumor-target alignment workflows and systematic geometric error reduction.
Organ-at-Risk Protection
Supports treatment margin management and radiation exposure management for healthy tissue.
These workflows support consistent patient care. For cancer centers, geometric reliability supports quality assurance workflows and clinical consistency.
Clinical & Technical Validation
Undergoing pilot-stage clinical evaluation.
PrecisionMRI.AI has completed clinical and technical assessments.
CLINICAL DEVELOPMENT STAGES
1
Technology Validation
Geometric reliability assessment initiated.
Evaluated across multiple MRI platforms.
Reproducibility assessed at pilot sites.
2
Clinical Integration
Early engagement agreements established.
Active evaluation programs underway.
Clinical teams assessing MR-in-RT workflows.
3
Regulatory Activities
FDA 510(k) pathway actively pursued.
Provisional patents formally filed.
Quality Management System (QMS) development underway.
4
Strategic Engagements
Engagement initiated for vendor-neutral implementation.
Advisory board includes experts from institutions.
Collaboration framework established with research institutions.
These milestones demonstrate technical readiness and initial clinical integration.
Competitive Landscape
Comparison reflects available MR-in-RT workflows and vendor capabilities.
Integrated Platform Positioning
PrecisionMRI.AI integrates hardware and AI to support quality assurance workflows and vendor-neutral implementation.
Clinical Partnerships
CLINICAL COLLABORATION
Collaborations facilitate clinical evaluation and MR-in-RT workflow integration. PrecisionMRI.AI partners with radiation oncology centers and MRI manufacturers to support technology validation and clinical pilot programs.
Clinical Pilot Sites
Pilot programs are active at radiation oncology centers.
These collaborations provide clinical evaluation of our platform.
Operational feedback informs platform refinement.
Evaluation of geometric reliability in clinical settings
Optimization of MR-in-RT integration
Assessment of reliability within treatment planning
Integration of patient-specific QA workflows
MRI Manufacturer Partnerships
We engage MRI manufacturers to explore integration.
This engagement facilitates platform compatibility across diverse clinical imaging systems.
Partnership opportunities include:
Technology integration for geometric distortion correction
Joint development initiatives
Technical collaboration for system compatibility
Clinical research collaborations
These engagements emphasize clinical and technical collaboration, distinct from commercial vendor partnerships. To explore collaboration opportunities, please contact us.
Developed by medical physicists with expertise in MR-in-RT workflows and quality assurance.
PrecisionMRI.AI is led by medical physicists experienced in MR-in-RT workflows, imaging quality assurance, and translational AI. The advisory board includes leaders from academic medical centers.
Executive Leadership
Executive Team
Ali Fatemi, Ph.D.
Founder & Chief Executive Officer
Clinical medical physicist focusing on MR-in-RT workflows and patient-specific quality assurance. Experienced in advanced imaging protocol development.
James Petell, Ph.D.
Co-Founder & Officer, Intellectual Property
Experienced in research, product development, and intellectual property management. USPTO Patent Agent.
Scientific & Clinical Advisors
Advisory Board
Daniel Low, Ph.D.
Vice Chair, Department of Radiation Oncology, UCLA
Recognized contributor to MR-in-RT workflows and medical physics.
His research supports MRI geometric reliability standards.